Daniel Castellano

9.2K posts

Daniel Castellano

Daniel Castellano

@cdanicas

Medical Oncologist. Hospital Univ. 12 de Octubre. Madrid. UCM. Head GU Unit. Executive Member @GUARDconsortitum

Katılım Ocak 2013
1.7K Takip Edilen3.9K Takipçiler
Daniel Castellano retweetledi
GUARD Consortium
GUARD Consortium@GuardConsortium·
🌍 Compartimos el Informe de Impacto 2025 de @UroTeragLATAM , que recoge sus principales avances en formación y educación en uroteragnosis. Entre los hitos, destaca la alianza con GUARD Consortium para desarrollar actividades académicas conjuntas en España. Consulta el informe completo 👇 uroteraglatam.com/wp-content/upl… #GUARDConsortium #UroTeragLATAM #Teragnosis #UroOncology @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1
GUARD Consortium tweet media
Español
0
6
9
520
Daniel Castellano retweetledi
Martín Angel
Martín Angel@Martin_AngelMD·
📢¿Queres aprender de +40 EXPERTOS de 12 países en un solo curso⁉️ 🌍🔥 V Curso Teragnóstico en Cáncer de Próstata 📆 Ago-Sep 2026 | 7 módulos | +21 hrs 💯 SIN COSTO 📲 Inscríbete ahora 👇 QR @UroTeragLATAM #CáncerDeProstata @OncoAlert
Martín Angel tweet mediaMartín Angel tweet mediaMartín Angel tweet media
Español
0
7
17
1.2K
Daniel Castellano retweetledi
Dra. María Natalia Gandur Quiroga
Dra. María Natalia Gandur Quiroga@nataliagandur·
🚨 The OncoAlert Newsletter | June 25 – July 1, 2026 is out! 📩 Register to receive it 👉 buff.ly/X6N7qLU 👉 buff.ly/4xd4naf 🔥 This week's featured story 🇪🇺 The European Commission approves trastuzumab deruxtecan as the first tumor-agnostic HER2-directed ADC for previously treated HER2-positive solid tumors—another milestone for biomarker-driven oncology and the expanding role of ADCs across tumor types. Read this and many more practice-changing updates in this week's newsletter. Pinging our global faculty & colleagues 👇 @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @AmandaNizamMD @DrVilmaPBarcia #OncoAlert #ADC #HER2 #PrecisionOncology #Oncology
OncoAlert@OncoAlert

The OncoAlert Newsletter June 25- July 1, ,2026 REGISTER TO GET IT👉 buff.ly/X6N7qLU or buff.ly/4xd4naf 🔥 Highlights include: 🔹 Industry Update: 🇪🇺 EU approval of trastuzumab deruxtecan as the first tumour-agnostic HER2-directed ADC for previously treated HER2-positive solid tumors — expanding the impact of biomarker-driven oncology. #ADC #PrecisionOncology #HER2 @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @amandaNizamMD @DrVilmaPBarcia

Buenos Aires City Region, Argentina 🇦🇷 English
0
2
10
1.4K
Daniel Castellano retweetledi
OncoAlert
OncoAlert@OncoAlert·
The latest @GuardConsortium Educational Capsule in collaboration with @OncoAlert 🚨is Now Out! This week: What is New in Bladder Cancer July 2026 with Dr. Felix Guerrero Ramos in this GUARD Educational capsule Dr Felix Guerrero Ramos🇪🇸@DrFelixGuerrero of Hospital 12 de Octubre in Madrid, Spain, takes us through the newest findings and approvals in #BladderCancer . This made possible through our partners at the GUARD Consortium @cdanicas @Ecastromarcos @dralvaropinto @drenriquegrande @nachoduranm @DrJaVallejo @abraocantoMD @docjavip @AlvarezMa89031 @DrFelixGuerrero @BerUrologia @AnaPlatabello1 @scocmem @OncBrothers @Helena_de_Palma @F_lopez_campos @mjuanfi81 Pinging our GU faculty @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @brian_rini @AOmlin @realbowtiedoc @AmandaNizamMD @scocmem
English
0
13
18
3.5K
Daniel Castellano retweetledi
OncoAlert
OncoAlert@OncoAlert·
📢 The OncoAlert Newsletter | This Week's Edition Is Out 🔥July 2-9 REGISTER TO GET IT👉 buff.ly/X6N7qLU or buff.ly/4xd4naf ⭐ SPOTLIGHT TRIAL: Adjuvant Pembrolizumab + Belzutifan for Renal-Cell Carcinoma — does adding a HIF-2α inhibitor to adjuvant immunotherapy change the game for high-risk resected ccRCC? The phase 3 data are in, and the efficacy-toxicity trade-off is worth a close look. Also in this edition: 🧬 Casdatifan's durable HIF-2α-driven response in refractory metastatic RCC 🩺 APCCC 2025: consensus reached on just 19% of prostate cancer diagnostic questions 🫁 Do PPIs blunt durvalumab's efficacy after chemoradiotherapy in stage III NSCLC? 🎯 [177Lu]Lu-edotreotide outperforming everolimus in GEP-NETs (COMPETE trial) 🎗️ Trastuzumab rezetecan nearly quadruples PFS in HER2+ metastatic breast cancer ➕ 4 more studies spanning lung, GI, breast, gyn onc, and multiple myeloma Curated for oncology professionals, by oncology professionals. Read the full edition 👉 OncoAlert360.com #OncologyNews #RenalCellCarcinoma #KidneyCancer #NSCLC #BreastCancer #NeuroendocrineTumors #MultipleMyeloma #Oncology #ClinicalResearch #OncoAlert @OncoAlert @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @amandaNizamMD @DrVilmaPBarcia
English
0
16
24
9.5K
Daniel Castellano retweetledi
Dra. María Natalia Gandur Quiroga
Dra. María Natalia Gandur Quiroga@nataliagandur·
🚨 The OncoAlert Newsletter | July 2–9 Edition is HERE! 📩 Register now 👉 buff.ly/X6N7qLU 👉 buff.ly/4xd4naf 🔥 This week's Spotlight Trial 🧬 LITESPARK-022: Does adding belzutifan to adjuvant pembrolizumab redefine the standard for high-risk resected clear-cell #KidneyCancer? Plus the latest practice-changing updates: ✅ Durable activity of casdatifan in refractory metastatic RCC ✅ APCCC 2025: Consensus reached in only 19% of prostate cancer diagnostic questions ✅ Do PPIs reduce the benefit of durvalumab after chemoradiotherapy in stage III #NSCLC? ✅ COMPETE: ¹⁷⁷Lu-edotreotide vs everolimus in GEP-NETs ✅ Trastuzumab rezetecan delivers a remarkable PFS benefit in HER2+ metastatic #BreastCancer ➕ Additional highlights across GI oncology, gynecologic cancers, and multiple myeloma. 📚 Curated by oncologists, for oncologists. 🌐 Read the full edition: OncoAlert360.com @OncoAlert Pinging our global faculty & colleagues 👇 @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @AmandaNizamMD @DrVilmaPBarcia #OncoAlert #Oncology #KidneyCancer #ProstateCancer #NSCLC #BreastCancer #PrecisionOncology #ClinicalResearch
OncoAlert@OncoAlert

📢 The OncoAlert Newsletter | This Week's Edition Is Out 🔥July 2-9 REGISTER TO GET IT👉 buff.ly/X6N7qLU or buff.ly/4xd4naf ⭐ SPOTLIGHT TRIAL: Adjuvant Pembrolizumab + Belzutifan for Renal-Cell Carcinoma — does adding a HIF-2α inhibitor to adjuvant immunotherapy change the game for high-risk resected ccRCC? The phase 3 data are in, and the efficacy-toxicity trade-off is worth a close look. Also in this edition: 🧬 Casdatifan's durable HIF-2α-driven response in refractory metastatic RCC 🩺 APCCC 2025: consensus reached on just 19% of prostate cancer diagnostic questions 🫁 Do PPIs blunt durvalumab's efficacy after chemoradiotherapy in stage III NSCLC? 🎯 [177Lu]Lu-edotreotide outperforming everolimus in GEP-NETs (COMPETE trial) 🎗️ Trastuzumab rezetecan nearly quadruples PFS in HER2+ metastatic breast cancer ➕ 4 more studies spanning lung, GI, breast, gyn onc, and multiple myeloma Curated for oncology professionals, by oncology professionals. Read the full edition 👉 OncoAlert360.com #OncologyNews #RenalCellCarcinoma #KidneyCancer #NSCLC #BreastCancer #NeuroendocrineTumors #MultipleMyeloma #Oncology #ClinicalResearch #OncoAlert @OncoAlert @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @amandaNizamMD @DrVilmaPBarcia

English
0
4
10
1.7K
Daniel Castellano retweetledi
OncoAlert
OncoAlert@OncoAlert·
This #WeekInOncology by @OncoAlert| GU Edition 🚨 Today, our GU Faculty Dr. Natalia Gandur 🇦🇷 reviews the LITESPARK-022 trial, led by OncoAlert Faculty member Dr. Toni K. Choueiri.🇺🇸 📄 Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma NEJM, July 1, 2026 LINK👉 buff.ly/OqaCA64 The phase 3 trial showed that adding the HIF-2α inhibitor belzutifan to adjuvant pembrolizumab after nephrectomy significantly improved disease-free survival in high-risk clear-cell RCC. 🔬 Key results: ➡️ DFS benefit: HR 0.72 (95% CI, 0.59–0.87; P<0.001) ➡️ 24-month DFS: 80.7% vs 73.7% ➡️ No significant OS difference at interim analysis ➡️ Higher grade ≥3 toxicities with combination therapy (52.1% vs 30.2%) 🎥 Watch Dr. Gandur’s expert discussion on this important advance in GU oncology. #KidneyCancer #GUOncology #RenalCellCarcinoma #Oncology #Immunotherapy #OncoAlert @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @AlbigesL @cdanicas @amerseburger @sonpavde @DrDanielHeng @declangmurphy @seanmmcbride @HHammersMD @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @scocmem @ravikanesvaran @AmandaNizamMD @drenriquegrande @BraunMDPhD @EfstathiouEleni @nataliagandur @crisbergerot @motzermd @PBarataMD @DrIacovelli
English
0
9
21
4.8K
Daniel Castellano retweetledi
GUARD Consortium
GUARD Consortium@GuardConsortium·
Ya está disponible una nueva GUARD Educational Capsule en colaboración con @OncoAlert El Dr. @DrFelixGuerrero, del @Urologia12 Hospital 12 de Octubre de Madrid, repasa las principales novedades y aprobaciones recientes en #BladderCancer. #GUARDConsortium #Oncology #MedicalEducation
OncoAlert@OncoAlert

The latest @GuardConsortium Educational Capsule in collaboration with @OncoAlert 🚨is Now Out! This week: What is New in Bladder Cancer July 2026 with Dr. Felix Guerrero Ramos in this GUARD Educational capsule Dr Felix Guerrero Ramos🇪🇸@DrFelixGuerrero of Hospital 12 de Octubre in Madrid, Spain, takes us through the newest findings and approvals in #BladderCancer . This made possible through our partners at the GUARD Consortium @cdanicas @Ecastromarcos @dralvaropinto @drenriquegrande @nachoduranm @DrJaVallejo @abraocantoMD @docjavip @AlvarezMa89031 @DrFelixGuerrero @BerUrologia @AnaPlatabello1 @scocmem @OncBrothers @Helena_de_Palma @F_lopez_campos @mjuanfi81 Pinging our GU faculty @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @brian_rini @AOmlin @realbowtiedoc @AmandaNizamMD @scocmem

Español
0
7
11
563
Daniel Castellano retweetledi
GUARD Consortium
GUARD Consortium@GuardConsortium·
🇪🇸 ES | ¿A quién va dirigido #QUANTUM? Pacientes con cáncer de próstata metastásico hormonosensible de alto volumen que han recibido terapia de primera línea con el triplete TDA + Docetaxel + Darolutamida y son candidatos a recibir Radium-223 de forma secuencial. Un perfil muy específico. Una oportunidad terapéutica muy concreta. 🇬🇧 EN | Who is #QUANTUM designed for? Patients with high-volume metastatic hormone-sensitive prostate cancer who have received first-line triplet therapy with ADT + Docetaxel + Darolutamide and are candidates for sequential Radium-223. A very specific patient profile. A very precise therapeutic opportunity. #ProstateCancer #mHSPC #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1
GUARD Consortium tweet media
Español
0
3
4
513
Daniel Castellano retweetledi
OncoAlert
OncoAlert@OncoAlert·
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer (ARC-20) out in nature buff.ly/nquFaVs Casdatifan, a selective HIF-2α inhibitor, demonstrated meaningful and durable antitumour activity with manageable safety in refractory metastatic clear cell renal cell carcinoma in the 🏹 ARC-20 study. Across 127 patients, confirmed objective response rates were 31–35% and median progression-free survival reached 12.2 months overall. Adverse events were mainly 🩸 anemia and hypoxia, with low discontinuation rates. Biomarker 🧬 analyses showed that greater suppression of erythropoietin and HIF-2α activity correlated with improved clinical outcomes and response. #KidneyCancer 🚨 #OncoAlertToniChoueiriDay @DrChoueiri @brian_rini @PBarataMD @DrRanaMcKay @MosheOrnsteinMD @BradMcG04 Pinging 🚨 faculty @montypal @crisbergerot @DrDanielHeng @apolo_andrea @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @AOmlin #OncoAlertAF @nataliagandur @realbowtiedoc @scocmem @AmandaNizamMD
OncoAlert tweet media
English
1
14
20
3.1K
Daniel Castellano retweetledi
Vivek Subbiah, MD
Vivek Subbiah, MD@VivekSubbiah·
⭐️Nice review in @JAMAOnc 👉 Circulating Tumor DNA in Early Breast Cancer. 👉Multiple ongoing prospective interventional trials are evaluating whether ctDNA-guided treatment escalation or de-escalation can improve patient outcomes and support the routine implementation of ctDNA assays in clinical practice jamanetwork.com/journals/jamao…
English
0
4
12
1.8K
Daniel Castellano retweetledi
OncoDaily GU
OncoDaily GU@OncoDailyGU·
CheckMate 214 final 9-year analysis The final CheckMate 214 analysis reports outcomes with nivolumab + ipilimumab vs sunitinib in previously untreated advanced RCC, with a median follow-up of 9.3 years. Key findings: • ITT median OS: 52.7 vs 37.8 months • 108-month OS: 31.4% vs 19.5% • IMDC intermediate/poor-risk median OS: 46.7 vs 26.0 months • IMDC intermediate/poor-risk median PFS: 12.4 vs 8.5 months • ORR: 42.4% vs 27.5% • No new safety signals These final results add long-term evidence for durable benefit with first-line nivolumab + ipilimumab in advanced RCC, particularly in IMDC intermediate- or poor-risk disease. @DrChoueiri @AlbigesL @BurottoMauricio @ERPlimackMD @Dr_SabyGeorge @tompowles1 @FDonskov @HowardGurney @ChristianK28850 @grimm_mo @cdanicas @ViktorGruenwald @motzermd oncodaily.com/genitourinary-… #RCC #KidneyCancer #GUOncology #Immunotherapy #CheckMate214
OncoDaily GU tweet media
English
0
5
20
852
Daniel Castellano retweetledi
Toni Choueiri, MD
Toni Choueiri, MD@DrChoueiri·
1/ Results from #ARC20 trial are out in @Nature! This trial evaluated the HIF-2α inhibitor Casdatifan in heavily pretreated advanced ccRCC and provides important insights into HIF-2α biology and response. This is the 2nd HIF2 inhibitor with enough activity to move to a pivotal study after Belzutifan, cementing the 2019 @nobelprize story with @kaelinlab et al Check it out: nature.com/articles/s4158…
Toni Choueiri, MD tweet media
English
10
63
163
13.7K
Daniel Castellano retweetledi
Vivek Subbiah, MD
Vivek Subbiah, MD@VivekSubbiah·
⭐️How many researchers have an NEJM paper and a Nature paper published on the same day? N = 1 Dr. @DrChoueiri 🚀 to the moon, Mars, & beyond @OncoAlert ! Huge congratulations 🎉
Vivek Subbiah, MD tweet mediaVivek Subbiah, MD tweet mediaVivek Subbiah, MD tweet media
English
9
25
194
25.8K
Daniel Castellano retweetledi
GUARD Consortium
GUARD Consortium@GuardConsortium·
🇪🇸 ES 🔬 GUARD Consortium impulsa #QUANTUM, un ensayo clínico de Fase II en cáncer de próstata metastásico hormonosensible de alto volumen. Triplete de inducción + Radium-223 secuencial en pacientes sin respuesta profunda tras terapia de primera línea. 📅 CTIS submission: Mayo 2026 | FSA: Q3 2026 | FPI: Q3 2026 #OncologíaUrinaria #CáncerDePróstata #EnsayoClínico 🇬🇧 EN 🔬 GUARD Consortium launches #QUANTUM, a Phase II pilot clinical trial in high-volume metastatic hormone-sensitive prostate cancer. Sequential Radium-223 after induction triplet therapy for patients with high-volume mHSPC. 📅 CTIS submission: May 2026 | FSA: Q3 2026 | FPI: Q3 2026 #ProstateCancer #ClinicalTrial #Oncology @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1
GUARD Consortium tweet media
Español
0
4
8
275
Daniel Castellano retweetledi
oncopromesas vs oncosaurios
oncopromesas vs oncosaurios@oncopromesas·
Tras pausa para el networking continúamos debatiendo sobre el #CáncerdePróstata en un bloque a cargo de de la Dra. Zulema Nogareda y Dr. Daniel Castellano @cdanicas. Moderan la #Mesa8 de #PromesasVsSaurios el Dr. Diego Cacho y la Dra. Remedios Quirce.
oncopromesas vs oncosaurios tweet media
Español
0
3
8
306

Keşfet

@UroTeragLATAM @DrFelixGuerrero @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo